Exhaled Breath Condensate Biomarkers in CARAS

Henan University of Traditional Chinese Medicine270 enrolled

Overview

To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.

Study Type

OBSERVATIONAL

Enrollment

270

Conditions

Combined Allergic Rhinitis and Asthma Syndrome

Interventions

questionnaire surveyOTHER

subjects fill out questionnaires

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria; * Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence; * Age 18 to 80 years; * Voluntarily accepted the study and signed an informed consent form; * Not participated in other clinical studies within 1 month before enrollment. Exclusion Criteria: * Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose; * Patients who are participating in other drug trials; * Patients with a combination of other serious systemic diseases; * Pregnant or lactating women; * Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.

Locations (1)

The First Affiliated Hospital of Henan University of Chinese Medicine

Henan, Zhengzhou, China

RECRUITING

Outcomes

Primary Outcomes

Interleukin-2、4、5、13 (IL-2、4、5、13)

Airway inflammation will be assessed using the IL-2、4、5、13.

Time frame: Basline

Interferon-γ (IFN-γ)

Airway inflammation will be assessed using the IFN-γ.

Time frame: Basline

Tumor necrosis factor-β (TNF-β)

Airway inflammation will be assessed using the TNF-β.

Time frame: Basline

Eosinophil cationic proteins (ECP)

Airway inflammation will be assessed using the ECP.

Time frame: Basline

Immunoglobulin E (IgE)

Airway inflammation will be assessed using the IgE.

Time frame: Basline

Secondary Outcomes

Fractional exhaled nitric oxide (FeNO)

Higher FeNO values indicate higher airway inflammation.

Time frame: Basline

Forced expiratory volume in one second (FEV1)

Lung function will be assessed using the FEV1.

Time frame: Basline

Forced vital capacity (FVC)

Lung function will be assessed using the FEV1.

Time frame: Basline

FVC as the percentage of the predicted value (FVC%)

Lung function will be assessed using the FVC%.

Central Contacts

Yang Xie

CONTACT

13526621325 xieyanghn@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.